Ascendis Pharma A/S announced topline results from Week 52 of the COACH Phase 2 clinical trial, evaluating combination therapy with once-weekly TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin) in children with achondroplasia. The combination therapy demonstrated durable growth, improvements in body proportionality and arm span, and was generally well tolerated with mild treatment-emergent adverse events. The annualized growth velocity exceeded the 97th percentile of average stature children, and height Z-score improvements indicated a tripling of efficacy compared to TransCon CNP monotherapy. All participants completed 52 weeks of treatment and remain on therapy. The Week 52 results have been presented and a slide presentation is available on the Ascendis Pharma website. Ascendis Pharma has submitted a protocol and held an end of Phase 2 meeting with the FDA regarding a Phase 3 trial of TransCon CNP and TransCon hGH in pediatric achondroplasia.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622597-en) on January 08, 2026, and is solely responsible for the information contained therein.
